Ferrone et al identified risk factors associated with survival in a patient with a resectable pancreatic adenocarcinoma. These can help identify a patient who may benefit from more aggressive or novel therapies. The authors are from Memorial Sloan-Kettering Cancer Center in New York and Massachusetts General Hospital in Boston.
Patient selection: resectable pancreatic adenocarcinoma (T1 to T3 and M0)
Parameters identified on multivariate analysis:
(1) change in the serum CA19-9 concentration before and after surgery
(2) serum concentration of CA19-9 after surgery
(3) T stage
(4) N stage (presence or absence of lymph node metastases)
Parameter |
Finding |
Points |
change in serum CA19-9 |
postoperative decrease or no change |
0 |
|
postoperative increase |
1 |
postoperative CA19-9 level |
<= 200 U/mL (<= 5.4 times ULN) |
0 |
|
> 200 U/mL (> 5.4 times ULN) |
1 |
T stage |
T1 or T2 |
0 |
|
T3 |
1 |
lymph node metastases |
absent (N0) |
0 |
|
present (N1) |
1 |
where:
• The upper limit of the normal reference range for serum CA19-9 was 37 U/mL.
• The odds ratios for the risk factors ranged from 2.5 to 3.2.
number of risk factors associated with increased mortality =
= SUM(points for all 4 parameters)
Interpretation:
• minimum score: 0
• maximum score: 4
• The higher the score the worse the survival.
Specialty: Hematology Oncology, Surgery, general, Gastroenterology
ICD-10: ,